Sort
4,870 grants matching “glp 1”
Development of TP-217 as a highly efficacious, broad-spectrum antibiotic for the
$828,940Anne Kathleen Radcliff · Cubrc, Inc. · R01 · FY2011 · AI
Direct protein phosphatase 2A (PP2A) activators as novel Alzheimerâs Disease (AD) therapeutics
$828,594Michael Ohlmeyer · Atux Iskay Group Llc · R44 · FY2025 · AG
A Novel Microbiome-Based Immune-Modulator that Potentiates Cancer Checkpoint Therapy
$828,114Gary Fanger · Rise Therapeutics, Llc · R44 · FY2023 · CA
Portable pneumatic driver for counterpulsation therapy
$827,886Paul A Spence · Scr, Inc. · R44 · FY2010 · HL
A Novel Immunological-Directed Synthetic Biology-Based Drug for the Treatment of Multiple Sclerosis
$827,713Christian Furlan Freguia · Rise Therapeutics, Llc · R44 · FY2025 · AI
Optimized lactoferrin for treatment of intracerebral hemorrhage
$827,468Marian L Kruzel · Pharmareview Corporation · R42 · FY2017 · NS
AAV-mediated gene therapy for GM2-gangliodoses
$827,235Miguel S Esteves · Univ Of Massachusetts Med Sch Worcester · U01 · FY2011 · NS
AAV-mediated gene therapy for GM2-gangliodoses
$827,235Miguel S Esteves · Univ Of Massachusetts Med Sch Worcester · U01 · FY2011 · NS
Treatment of Transplant Reperfusion with CD47 antibody
$827,018Pamela Ann Toy-Manning · Vasculox, Inc. · R44 · FY2013 · HL
Anti-biofilm agents for the treatment of pulmonary infection in cystic fibrosis p
$826,326David Jung · Agile Sciences, Inc. · R42 · FY2015 · AI
Drug Development of GLP-1 receptor agonists
$826,149Josephine Egan · National Institute On Aging · ZIA · FY2014 · AG
Development of Novel and Affordable Neoglycosylated, Long Acting Superactive Analog of Human FSH for Infertility
$825,420Bruce Dale Weintraub · Trophogen, Inc. · R44 · FY2018 · HD
Targeting GI Epithelial Integrity to Improve Arterial Inflammation in HIV
$822,455Janet Lo · Massachusetts General Hospital · R01 · FY2017 · HL
Thioredoxin mimicry: novel treatment of toxicant-mediated inhalational lung injur
$821,853Garry John Southan · Radikal Therapeutics, Inc. · U01 · FY2018 · ES
Vascular CT contrast agent development
$821,821Michael A Davis · Nextrast, Inc. · R44 · FY2022 · HL
Manufacturing and Toxicology Studies of DNA and Protein Vaccines
$819,711Gary R Ostroff · Univ Of Massachusetts Med Sch Worcester · U19 · FY2009 · AI
Development of a novel class of immunotherapeutic antibody for metastatic prostate cancer
$818,940Grant H Risdon · Cancure, Llc · R44 · FY2019 · CA
CV Benefits and Safety of Glucose-Lowering Therapies in Adults with Diabetes
$818,099Patrick J O'Connor · Healthpartners Institute · R01 · FY2014 · HL
Pulmonary valved conduit xenograft with regeneration potential
$817,553Ajay Houde · Annoviant, Inc · R44 · FY2021 · HL
Inhalational therapy with spectinamides within new regimens of TB therapy
$817,405Mercedes Gonzalez-Juarrero · Colorado State University · R01 · FY2024 · AI
Stable Glucagon for Treatment of Hyperinsulinism
$816,607Pawel Fludzinski · Amidebio, Llc · R44 · FY2020 · DK
GMP Production and Extended Toxicology of an Oral Formulation Drug for Alzheimer's Disease
$815,581D. Martin Watterson · Northwestern University At Chicago · U01 · FY2025 · AG
Nitrite dependent protection against Cl2 gas toxicity_role of chlorinated lipids
$815,300Rakesh Pravinchandra Patel · University Of Alabama At Birmingham · U01 · FY2016 · ES
Nitrite dependent protection against Cl2 gas toxicity_role of chlorinated lipids
$815,300Rakesh Pravinchandra Patel · University Of Alabama At Birmingham · U01 · FY2015 · ES
Virtual systemic identification of drug targets of obesity candidate genes
$815,091Yingchang Lu · Vanderbilt University Medical Center · R01 · FY2023 · DK